An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the gut microbiota of constipated Parkinson's disease patients (C-PD), non-constipated Parkinson's disease patients (NC-PD), and healthy controls. They aimed to clarify whether constipation, a common non-motor symptom of Parkinson's disease, is linked to distinct gut microbiota changes.
How was it studied?
The team performed 16S rRNA sequencing on stool samples from 15 C-PD patients, 14 NC-PD patients, and 15 healthy controls. They built co-occurrence networks to compare gut ecology across groups and used Spearman correlation to relate differential microbiota to clinical features.
What did they find?
Beta diversity differed significantly among the three groups, though alpha diversity did not. Compared with healthy controls, Parkinson's patients had increased Hungatella and Collinsella and reduced Lachnospira and Fusicatenibacter. Compared with NC-PD patients, the C-PD group had lower Megamonas and Holdemanella but higher Hungatella, Streptococcus, and Anaerotruncus, with a distinct co-occurrence network structure.
Why it matters
The findings link specific gut bacteria to constipation in Parkinson's disease and to broader clinical features of the disease. The authors suggest modulating gut microbiota could offer a way to monitor or optimize Parkinson's disease treatment.